Literature DB >> 11044172

Pattern of recurrence following radical oesophagectomy with two-field lymphadenectomy.

S M Dresner1, S M Griffin.   

Abstract

BACKGROUND: Despite increasingly radical surgery for oesophageal cancer, many patients continue to develop recurrent disease. The aim of this study was to evaluate the pattern of failure following attempted curative oesophagectomy with two-field lymphadenectomy for adenocarcinoma and squamous cell carcinoma of the middle and lower third of the oesophagus.
METHODS: A total of 176 consecutive patients discharged from hospital following R0 resection between 1 April 1990 and 31 December 1999 were followed for evidence of recurrence over a mean interval of 26 months.
RESULTS: Adenocarcinoma was the predominant histological subtype (n = 113) compared with squamous cell carcinoma (n = 63). Sex and age distribution were similar for both histological subtypes (M:F ratio 2.5:1, median age 64 (range 40-77) years). Overall 2- and 5-year survival rates were 54 and 31 per cent respectively. Some 85 patients (48 per cent) developed proven recurrence, of whom five are alive and 80 dead. The median time to recurrence was 11.7 (range 1. 5-67) months, with a median survival thereafter of only 2.7 (0-25.9) months. The pattern of recurrence was locoregional in 27 per cent (mediastinal 21 per cent and cervical 6 per cent) and distant in 18 per cent (liver 6 per cent, bone 6 per cent, cerebral 2 per cent, peritoneal 2 per cent, lung 1 per cent, skin 1 per cent). There was no difference in the overall pattern of dissemination or timing of recurrence for either histological subtype. Over 50 per cent of all recurrences occurred within 12 months of surgery, with local, regional and distant recurrence occurring at a median of 11.9 (range 1.8-52), 11.0 (range 5-67) and 11.0 (1.5-58) months respectively.
CONCLUSION: The low incidence of cervical recurrence suggests that a more extensive 'three-field' lymphadenectomy is unlikely to improve survival rates. Better staging modalities are needed to identify patients who will have recurrence within 12 months of operation, so that they may be either entered into trials of multimodality treatment or offered non-surgical palliation. British Journal of Surgery prize-winning paper, presented to the Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland, London, UK, September 1999

Entities:  

Mesh:

Year:  2000        PMID: 11044172     DOI: 10.1046/j.1365-2168.2000.01541.x

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  47 in total

Review 1.  Multimodality therapy for gastroesophageal cancers.

Authors:  Kenneth K Wang
Journal:  J Gastrointest Surg       Date:  2002 Jul-Aug       Impact factor: 3.452

2.  Chained time trade-off and standard gamble methods. Applications in oesophageal cancer.

Authors:  Paul McNamee; Sharon Glendinning; Jonathan Shenfine; Nick Steen; S Michael Griffin; John Bond
Journal:  Eur J Health Econ       Date:  2004-02

Review 3.  Multimodal treatment for resectable esophageal cancer.

Authors:  Hiroshi Miyata; Makoto Yamasaki; Yukinori Kurokawa; Shuji Takiguchi; Kiyokazu Nakajima; Yoshiyuki Fujiwara; Masaki Mori; Yuichiro Doki
Journal:  Gen Thorac Cardiovasc Surg       Date:  2011-07-14

4.  Surgical outcomes in esophageal cancer patients with tumor recurrence after curative esophagectomy.

Authors:  Chikara Kunisaki; Hirochika Makino; Ryo Takagawa; Naoto Yamamoto; Yasuhiko Nagano; Syoichi Fujii; Takashi Kosaka; Hidetaka A Ono; Yuichi Otsuka; Hirotoshi Akiyama; Yasushi Ichikawa; Hiroshi Shimada
Journal:  J Gastrointest Surg       Date:  2007-10-20       Impact factor: 3.452

5.  Recurrence pattern of squamous cell carcinoma in the middle thoracic esophagus after modified Ivor-Lewis esophagectomy.

Authors:  Gang Chen; Zhou Wang; Xiang-Yan Liu; Fan-Ying Liu
Journal:  World J Surg       Date:  2007-05       Impact factor: 3.352

6.  Prognostic factors for post-recurrence survival in esophageal squamous cell carcinoma patients with recurrence after resection.

Authors:  Po-Kuei Hsu; Bing-Yen Wang; Chien-Sheng Huang; Yu-Chung Wu; Wen-Hu Hsu
Journal:  J Gastrointest Surg       Date:  2011-02-15       Impact factor: 3.452

7.  Effect and mechanism of RUNX3 gene on biological characteristics of human esophageal squamous cell carcinoma (ESCC).

Authors:  Huaxia Chen; Zhou Wang; Shuai Wang; Zhiping Zhang; Shanshan Shi
Journal:  Med Oncol       Date:  2014-11-27       Impact factor: 3.064

8.  Risk of metastasis in adenocarcinoma of the esophagus: a multicenter retrospective study in a Japanese population.

Authors:  Ryu Ishihara; Tsuneo Oyama; Seiichiro Abe; Hiroaki Takahashi; Hiroyuki Ono; Junko Fujisaki; Mitsuru Kaise; Kenichi Goda; Kenro Kawada; Tomoyuki Koike; Manabu Takeuchi; Rie Matsuda; Dai Hirasawa; Masayoshi Yamada; Junichi Kodaira; Masaki Tanaka; Masami Omae; Akira Matsui; Takashi Kanesaka; Akiko Takahashi; Shinichi Hirooka; Masahiro Saito; Yosuke Tsuji; Yuki Maeda; Hiroharu Yamashita; Ichiro Oda; Yasuhiko Tomita; Takashi Matsunaga; Shuji Terai; Soji Ozawa; Tatsuyuki Kawano; Yasuyuki Seto
Journal:  J Gastroenterol       Date:  2016-10-18       Impact factor: 7.527

9.  Factors influencing the risk of recurrence in patients with esophageal carcinoma treated with surgery: A single institution analysis consisting of 1002 cases.

Authors:  Yaping Xu; Qixun Chen; Xinmin Yu; Ximing Zhou; Xiao Zheng; Weimin Mao
Journal:  Oncol Lett       Date:  2012-10-30       Impact factor: 2.967

10.  Postoperative extended-volume external-beam radiation therapy in high-risk esophageal cancer patients: a prospective experience.

Authors:  E Yu; P Tai; J Younus; R Malthaner; P Truong; L Stitt; G Rodrigues; R Ash; R Dar; B Yaremko; A Tomiak; B Dingle; M Sanatani; M Vincent; W Kocha; D Fortin; R Inculet
Journal:  Curr Oncol       Date:  2009-08       Impact factor: 3.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.